During the past decade, Praxis Bohl-Bühler conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Praxis Bohl-Bühler" #1 collaborator was "Wyeth is now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Praxis Bohl-Bühler" are "Ankylosing Spondylitis" (1 trials) and "Moderate to Severe Active Axial Spondyloarthritis" (1 trials). Many other conditions were trialed in "Praxis Bohl-Bühler" in a lesser frequency.

Most popular intervention types in "Praxis Bohl-Bühler" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Etanercept 25mg" (1 trials), "Sulfasalazine" (1 trials) and "diclophenac" (1 trials). Other intervention names were less common.

The vast majority of trials in "Praxis Bohl-Bühler" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Praxis Bohl-Bühler". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Praxis Bohl-Bühler, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Praxis Bohl-Bühler, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".